$RYTM Cashflow Statement | Understand Stock

$RYTM

$89.47 +$0.20 (0.22%) Close

$RYTM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Gain on sale of priority review voucher
Depreciation and amortization
Non-cash interest expense
Non-cash accretion & amortization of short-term investments
Non-cash rent expense
Loss on RareStone equity investment
Change in fair value of embedded derivative liability
Gain on settlement of forward contract
Acquired IPR&D assets classified as investing activities
Other non-cash items
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Deferred revenue
Other long-term assets, net
Accounts payable, accrued expenses and other liabilities

Net cash used in operating activities
Investing activities
Purchases of short-term investments
Maturities of short-term investments
Proceeds from sale of priority review voucher
Proceeds from out-license agreement
Acquisition of IPR&D assets
Payment of milestone obligation under license agreement
Purchases of property and equipment
Net cash used in investing activities

Financing activities
Repayment of deferred royalty obligation
Proceeds from issuance of common stock upon completion of public offering, net of offering costs
Proceeds from the exercise of stock options
Proceeds from issuance of common stock from ESPP
Proceeds from royalty financing agreement, net of issuance costs
Gain on settlement of forward contract
Proceeds from Series A Preferred Stock, net of issuance costs
Net cash provided by financing activities
Effect of exchange rates on cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of non-cash investing and financing activities:
Non-current liability issued in exchange for the acquisition of IPR&D
Issuance of common stock in exchange for IPR&D
Accretion of preferred stock dividends

Comments